Histogen Inc. (HSTO) shares gained 1.69% in after-hours on Monday, December 27, 2021, and closed the daily trading at $0.35. However, in the regular trading session, HSTO’s stock lost 6.77%. HSTO shares have fallen 71.32% over the last 12 months, and they have moved down 11.52% in the past week. Over the past three months, the stock has lost 56.68%, while over the past six months, it has declined 69.54%.
Let’s have a brief look at its recent news.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
>> 7 Top Picks for the Post-Pandemic Economy <<
HSTO closed a private placement of common stock
On December 21, 2021, Histogen Inc. (HSTO), closed its previously announced private placement for the issuance and sale of 8,235,297 shares of common stock and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock and associated warrant.
The company will get gross proceeds of $3.5 million from the offer and will use net proceeds for working capital and general corporate purposes.
HSTO latest financial results
On November 10, 2021, Histogen Inc. (HSTO), released its financial results for the third quarter ended September 30, 2021.
Q3 2021 financial highlights
- HSTO total revenue in Q3 2021 was $591,000 compared to $495,000 in Q3 2020.
- Research and development expenses were $2.3 million in Q3 2021 compared to $1.5 million in Q3 2020.
- General and administrative expenses were $2.1 million in Q3 2021 compared to $2.0 million in Q3 2020.
- It suffered a net loss of $3.86 million in Q3 2021 compared to a $3.3 million loss in Q3 2020.
- The company ended the third quarter with cash and cash equivalents of $19.2 million.
HSTO data presentation at a recent conference
Histogen Inc. (HSTO), and its partner, Amerimmune, LLC, presented updated findings from the emricasan Phase 1 study in mild symptomatic COVID-19 patients at the American College of Allergy, Asthma, and Immunology Conference in New Orleans which was held on November 6, 2021.
The Phase 1 trial showed excellent safety in early-stage, mildly symptomatic COVID-19 patients in a small cohort of individuals that received orally-dosed emricasan.
>> 7 Top Picks for the Post-Pandemic Economy <<
Conclusion
The recent private placement of common stock could be the reason behind its loss as we have no other recent news. let’s see how it commences trading on Tuesday?
